Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anatara Lifesciences Ltd ( (AU:ANR) ) has provided an announcement.
Anatara Lifesciences Ltd announced the completion of Stage 2 of its GaRP-IBS Phase II trial, which showed no safety concerns but did not meet the primary efficacy endpoint. However, secondary endpoints, such as a reduction in IBS symptom severity and improvement in anxiety scores, were achieved. The company also reported progress in its anti-obesity project and secured a patent for GaRP in Hong Kong, expanding its intellectual property protection. Additionally, Anatara received a $0.969 million R&D tax incentive refund from the Australian Government, providing financial support for its ongoing research activities.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a developer of evidence-based, innovative products focused on addressing significant unmet needs in human health, particularly conditions involving the gastrointestinal tract (GIT).
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$1.71M
Learn more about ANR stock on TipRanks’ Stock Analysis page.